Corporate Banner
Satellite Banner
Molecular & Clinical Diagnostics
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Insight Genetics Awarded NCI Contract

Published: Tuesday, January 07, 2014
Last Updated: Tuesday, January 07, 2014
Bookmark and Share
Company receives Phase II Award to continue development of a companion diagnostic test for drugs targeting anaplastic lymphoma kinase.

Insight Genetics, Inc. announce it has received a new $1.5 million Phase II Small Business Innovation Research (SBIR) contract from the National Cancer Institute (NCI).  A continuation of a Phase I contract NCI awarded to Insight Genetics in 2011, the new contract will allow the company to continue its development of Insight ALK Resistance™, a diagnostic test that helps clinicians monitor their non-small cell lung cancer (NSCLC) patients for resistance to their prescribed cancer therapy.

“Resistance is a growing concern in the cancer treatment world,” said Eric Dahlhauser, Chairman and CEO of Insight Genetics. “The Insight ALK Resistance assay meets a significant unmet need in non-small cell lung cancer by giving physicians a way to monitor their patients for drug resistance and providing information to help them determine the most effective course of treatment. Our team is delighted to continue our collaboration with the NCI to create companion diagnostic tests that can enhance how cancer is diagnosed, treated and monitored.”

Targeted therapeutics have been developed that effectively inhibit known genetic drivers of NSCLC such as EGFR and anaplastic lymphoma kinase (ALK). However, most patients develop resistance to their prescribed inhibitor within a year, making it no longer effective. Inhibitor resistance is driven by mutations in either the primary oncogenic gene or a separate gene in a secondary pool of cancer cells. Identification of the genetic driver of a patient’s inhibitor resistance can help a physician choose the appropriate ongoing treatment for the patient, which could include a next-generation inhibitor or other therapy that targets a separate oncogenic driver.

Insight ALK Resistance is a qPCR-based test that is customizable to detect all clinically identified resistance mutations in the ALK kinase domain or specific mutations, providing results within 48 hours and with minimal tissue requirement. The test can be used for various applications, including providing guidance in monitoring treatment efficacy, clinical decision making for alternative treatments, clinical trial enrollment for next-generation ALK inhibitors, or investigational academic research. Insight Genetics has obtained an exclusive worldwide license from St. Jude Children’s Research Hospital for the detection of ALK inhibitor resistance mutations.

This SBIR award is Insight Genetics’ sixth contract and third consecutive Phase II contract from NCI’s Companion Diagnostics program. It will allow Insight Genetics to further refine Insight ALK Resistance toward a Premarket Approval Application (PMA) with the U.S. Food and Drug Administration.  

Insight ALK Resistance is currently offered by Insight Molecular Labs, the CLIA-certified subsidiary of Insight Genetics, as a laboratory-developed test. Insight Molecular Labs provides support services for clinical trials on targeted therapeutics, including the identification of appropriate patients for trials, and specializes in the detection and monitoring of molecular-driven drug resistance in patients being treated with specific cancer therapies.


Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,500+ scientific posters on ePosters
  • More than 3,700+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Insight Genetics Announces Promotions for Two Team Members
Kasey Lawrence has been named Senior Technology Specialist, and Tyler Nielsen has been appointed Research Scientist.
Thursday, August 21, 2014
Insight Genetics and Vanderbilt-Ingram Cancer Center Partner
Research collaboration includes exclusive licensing agreement to commercialize a new genetic test that will improve treatment selection for breast cancer patients with poor prognosis.
Wednesday, March 05, 2014
Insight Genetics Launches Insight Molecular Labs
CLIA-certified laboratory offers diagnostic tests that identify specific cancer biomarkers.
Friday, December 13, 2013
Insight Genetics and National Cancer Institute Collaborate to Develop New Technologies for Clinical Trials
Insight Genetics has developed a diagnostic test that can more accurately determine if certain lung cancer patients will respond to targeted therapies.
Tuesday, April 02, 2013
Insight Genetics Promotes Four
Molecular diagnostics company builds expertise and depth in research, application and commercial development of companion diagnostics to improve cancer care.
Wednesday, February 13, 2013
Insight Genetics Awarded Qualifying Therapeutic Discovery Program Grant
Diagnostics Company Receives Funds to Advance Cancer Care.
Wednesday, November 17, 2010
Scientific News
Liquid Biopsies: Utilization of Circulating Biomarkers for Minimally Invasive Diagnostics Development
Market Trends in Biofluid-based Liquid Biopsies: Deploying Circulating Biomarkers in the Clinic. Enal Razvi, Ph.D., Managing Director, Select Biosciences, Inc.
Ultrafast DNA Diagnostics
New technology developed by UC Berkeley bioengineers promises to make a workhorse lab tool cheaper, more portable and many times faster by accelerating the heating and cooling of genetic samples with the switch of a light.
Long Telomeres Associated with Increased Lung Cancer Risk
Genetic predisposition for long telomeres predicts increased lung adenocarcinoma risk.
Paving the way to Better Ovarian Cancer Diagnosis
Aïcha BenTaieb will present her invention for automated identification of ovarian cancer’s many subtypes at an international conference this fall.
The Genetic Roots of Adolescent Scoliosis
Scientists at the RIKEN Center for Integrative Medical Sciences in collaboration with Keio University in Japan have discovered a gene that is linked to susceptibility of Scoliosis.
Diagnostic Test Developed for Enterovirus D68
researchers at Washington University School of Medicine in St. Louis have developed a diagnostic test to quickly detect enterovirus D68 (EV-D68), a respiratory virus that caused unusually severe illness in children last year.
Tracking Breast Cancer Before it Grows
A team of scientists led by University of Saskatchewan researcher Saroj Kumar is using cutting-edge Canadian Light Source techniques to screen and treat breast cancer at its earliest changes.
The Light of Fireflies for Medical Diagnostics
EPFL scientists have exploited the light of fireflies in a new method that detects biological molecules without the need for complex devices and high costs.
Could a simple saliva test detect Alzheimer's?
Researchers have presented findings suggesting that a simple, non-invasive diagnostic for Alzheimer's could be within reach.
Cheap Diagnostics with a Portable "Paper Machine"
Scientists have developed a cheap, portable system for point of care diagnostics for a range of infectious diseases, genetic conditions and cancer.
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,500+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,700+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FREE!